ZYNLONTA J Code: J9359

Drug & Product Overview

HCPCS Descriptor Injection, loncastuximab tesirine-lpyl, 0.075 mg

HCPCS Added Date April 1, 2022

Manufacturer ADC Therapeutics

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution

About ZYNLONTA

Zynlonta is a medication aligned to the HCPCS J Code: J9359 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by ADC Therapeutics.

According to CMS Drug Use Information: Loncastuximab tesirine is used to treat a certain type of cancer (large B-cell lymphoma). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
79952-0110-01	Zynlonta	ADC Therapeutics America, Inc.	134	10 MG / 2 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

ZYNLONTA Pricing & Reimbursement

J9359 Private Payer Reimbursement

$228.39 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

ZYNLONTA Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 13.14%

Avg. Days to File 8.7days

Avg. Days to Pay 27.4days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9359 claims analytics on FocalPoint →

ZYNLONTA CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Zynlonta (J9359) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

ZYNLONTA Medically Unlikely Edits (MUE)

The most billing units of J9359 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.075 mg.

Practitioner Office & Hospital Outpatient

400 units / day

= 30 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

ZYNLONTA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

relapsed or refractory large B-cell lymphoma

Frequently Asked Questions

Is there an available Zynlonta billing and coding guide?

Billing and coding information for ZYNLONTA can be found through ADC Therapeutics. Visit Here →

Are there any available Zynlonta patient assistance programs?

ZYNLONTA patient assistance information can be found through ADC Therapeutics. Visit Here →

Where can I find Zynlonta prescribing information?

ZYNLONTA prescribing information can be found at the link below: Visit Here →

Where can I find Zynlonta side effect information?

Information regarding ZYNLONTA's side effects can be found at MedlinePlus Visit Here →

Does billing ZYNLONTA require JZ/JW wastage modifiers?

CMS has identified ZYNLONTA(J9359) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.